Hormone · FDA Approved
Gonadorelin (GnRH)
FDA-approved
01 · Overview
A synthetic decapeptide identical to endogenous gonadotropin-releasing hormone. A pulsatile pattern of GnRH is required for pituitary stimulation and release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) (PMID 37223766).
Continuous or high-dose exposure instead downregulates GnRH receptors and suppresses gonadotropin secretion, the principle exploited by GnRH agonist therapeutics. US gonadorelin products (Factrel and Lutrepulse) were FDA-approved but are now listed as discontinued.
02 · Research summary & key findings
Previously FDA-approved as Factrel (1982) for diagnostic evaluation of pituitary gonadotropin function and as the Lutrepulse pump kit (1989) for pulsatile therapy; both are now listed as discontinued in the US. Pulsatile GnRH is used to treat anovulation and male hypogonadotropic hypogonadism, and avoids ovarian hyperstimulation while limiting multiple pregnancies (PMID 37223766). A meta-analysis of 35 studies in 1,002 women with hypothalamic amenorrhea found high ovulation rates, mostly singleton pregnancies, and a low, mild incidence of OHSS with pulsatile GnRH (PMID 29605411).
03 · Regulatory status
Gonadorelin (GnRH) has received FDA approval and is available for clinical use under appropriate medical supervision. Consult a qualified healthcare provider for prescribing information.
Gonadorelin (GnRH) is an FDA-approved medicine prescribed for the conditions on its label. It is not part of our intake, so we do not propose protocols for it. If you think it may be relevant to you, talk to your own doctor. How to ask your doctor.
Looking for a lawful, clinician-prescribed option for hormone optimization?
Gonadorelin (GnRH) is prescribed for the conditions on its label, and it is not part of our intake. If you are working on hormone optimization, a licensed clinician can tell you at a free consultation whether an FDA-approved or lawfully compounded treatment fits you, or whether nothing does.
Explore lawful options (free intake)About 3 minutes. If a protocol is prescribed through our provider, we earn 10% of the sale. See the receipts.
04 · Administration routes
- Intravenous
- Subcutaneous injection
References
- [1]Efficacy and safety of pulsatile gonadotropin-releasing hormone therapy among patients with idiopathic and functional hypothalamic amenorrhea: a systematic review of the literature and a meta-analysis Fertil Steril, 2018. PMID 29605411
- [2]Pulsatile gonadotropin-releasing hormone: clinical applications of a physiologic paradigm F S Rep, 2023. PMID 37223766
Primary literature
- PubMed: "Gonadorelin"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Gonadorelin"
Registered interventional and observational studies, including status and phase.
- PubChem: "Gonadorelin"
Chemical structure, molecular properties, and bioactivity data.
Related peptides in Hormone
Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed. Clinicians: join the network.